Panacea Biotec Announces AGM on Sep 29, 2026, with Book Closure Sep 25-29
Panacea Biotec Limited will hold its 42nd Annual General Meeting on September 29, 2026, via Video Conferencing. The book closure for the AGM is from September 25 to September 29, 2026. The meeting will adopt the FY26 audited financial statements and re-appoint directors. Mr. Rajinder Singh Manku will be appointed as an independent director.
This is a standard corporate event (AGM) with routine agenda items. The book closure dates are procedural and do not directly impact the company's operations or financial performance in a significant way.
The announcement is a routine procedural update regarding the Annual General Meeting, including book closure dates and agenda items. It does not contain significant new financial information or strategic developments that would strongly influence sentiment.
Panacea Biotec Limited has announced that its 42nd Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 11:30 AM IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
As a procedural step for the AGM, the Register of Members and Share Transfer Books will remain closed from Friday, September 25, 2026, to Tuesday, September 29, 2026, inclusive of both days.
The AGM agenda includes the consideration and adoption of the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. Additionally, the meeting will address the re-appointment of two directors, Mr. Ankesh Jain and Mr. Harshet Jain, who are retiring by rotation. Special business includes the appointment of Mr. Rajinder Singh Manku as an independent director for a period of five years from July 01, 2026, and the ratification of remuneration for the Cost Auditors, M/s Jain Sharma & Associates, for the financial year 2026-27 at ₹1,25,000 plus applicable taxes and expenses.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.